The global shingles vaccine market size is estimated at US$ 2.71 billion in 2024. The market is analyzed to climb to a value of US$ 5.97 billion by the end of 2034, expanding at a CAGR of 8.2% from 2024 to 2034.
The Shingles Vaccine Market is an essential segment of the global vaccines market, driven by the need to prevent shingles, a painful and debilitating condition caused by the reactivation of the varicella-zoster virus (VZV), which also causes chickenpox. Shingles, also known as herpes zoster, typically affects older adults and individuals with weakened immune systems, leading to a growing demand for effective vaccination strategies as the global population ages.
The market is primarily fueled by the increasing incidence of shingles, particularly among the elderly. As life expectancy rises, a larger proportion of the population is at risk of developing shingles, which can result in severe complications such as postherpetic neuralgia (PHN), a chronic pain condition that can persist long after the rash has healed. The growing awareness of these risks, combined with the availability of effective vaccines, has significantly boosted the demand for shingles vaccines.
For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=10175
Currently, two vaccines dominate the market: Zostavax, developed by Merck & Co., and Shingrix, developed by GlaxoSmithKline (GSK). Zostavax, a live attenuated vaccine, was the first shingles vaccine to receive approval in 2006 and has been widely used since then. However, its efficacy tends to decrease with age, particularly in individuals over 70.
In contrast, Shingrix, a recombinant, adjuvanted vaccine, was approved in 2017 and quickly became the preferred choice due to its higher efficacy, even in older adults. Shingrix’s two-dose regimen and strong protection against shingles and PHN have made it the gold standard in shingles prevention.
The shingles vaccine market is poised for significant growth in the coming years, driven by several key factors. First, the increasing adoption of vaccination programs targeting older adults is expected to expand the market. Many countries, particularly in North America and Europe, have implemented or are considering national immunization programs for shingles, which will further drive vaccine uptake. Additionally, the aging global population, particularly in developed regions, will continue to be a major driver of market growth.
Key Companies Profiled
Cipla Inc.; Pfizer Inc.; Merck & Co., Inc.; SK Chemicals; Vaccitech; CanSinoBIO; Green Cross Corp.; GlaxoSmithKline Plc.; GeneOne Life Science.
The regulatory landscape plays a crucial role in the market dynamics, as vaccines must undergo rigorous testing and approval processes to ensure their safety and efficacy. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are key regulatory bodies that oversee the approval and monitoring of shingles vaccines. The success of Shingrix, for example, can be attributed to the thorough clinical trials and subsequent endorsements by these agencies, which bolstered public confidence in the vaccine.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=10175
Geographically, North America holds the largest share of the shingles vaccine market, driven by high healthcare expenditure, strong vaccine adoption rates, and the presence of major market players. Europe also represents a significant market, with widespread immunization programs and increasing awareness of shingles among the aging population. The Asia-Pacific region is expected to witness the highest growth rate in the coming years, fueled by a rapidly aging population, increasing healthcare access, and growing awareness of the benefits of vaccination.
Segmentation of Shingles Vaccine Market Research
By Type :
Shingrix
Zostavax
Sky Zoster
Vaccine Type :
Recombinant Vaccines
Live Attenuated Vaccines
By End User :
Government Healthcare Settings
Private Healthcare Settings
By Region :
North America
Western Europe
Eastern Europe
Latin America
East Asia
South Asia & Pacific
Middle East & Africa